In breast cancer patients with human epidermal growth factor receptor 2 (HER2) status positive, supplementing trastuzumab subsequently after systemic chemotherapy significantly improves DFS, OS, and PFS in HER2 positive breast cancer both in adjuvant and in metastatic settings [7,8,9,10]. This evidence concerns the gene ERBB2 and breast carcinoma.